These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33126934)

  • 1. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis.
    Wu Y; Zhang Y; Wang Y; Wei J; Wang W; Duan W; Tian Y; Ren M; Li Z; Wang W; Zhang T; Wu H; Huang X
    Pharmacol Res; 2022 Aug; 182():106336. PubMed ID: 35779814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis.
    Tack I; Dumicho A; Ohler L; Shigayeva A; Bulti AB; White K; Mbatha M; Furin J; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3563-e3571. PubMed ID: 33372989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
    Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
    BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
    Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Replacing Linezolid with OTB-658 in Anti-Tuberculosis Regimens in Murine Models.
    Liu H; Zhu H; Fu L; Zhang W; Chen X; Wang B; Guo S; Ding Y; Wang N; Li D; Lu Y
    Antimicrob Agents Chemother; 2023 Feb; 67(2):e0139922. PubMed ID: 36622240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
    Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Antiretroviral Therapy on Treatment Outcomes in a Prospective Study of Extensively Drug-Resistant Tuberculosis (XDR-TB) HIV Coinfection Treatment in KwaZulu-Natal, South Africa.
    Yuengling KA; Padayatchi N; Wolf A; Mathema B; Brown T; Horsburgh CR; OʼDonnell MR
    J Acquir Immune Defic Syndr; 2018 Dec; 79(4):474-480. PubMed ID: 30212394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
    Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early mortality during rifampicin-resistant TB treatment.
    Mohr-Holland E; Daniels J; Reuter A; Rodriguez CA; Mitnick C; Kock Y; Cox V; Furin J; Cox H
    Int J Tuberc Lung Dis; 2022 Feb; 26(2):150-157. PubMed ID: 35086627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
    Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
    Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.